This trial is testing ibrutinib given with trastuzumab to see if it is safe and what the highest dose that can be given is. It is for people with HER2-positive metastatic breast cancer that has gotten worse after other treatments.
2 Primary · 6 Secondary · Reporting Duration: 24 months
26 Total Participants · 4 Treatment Groups
Primary Treatment: Trastuzumab · No Placebo Group · Phase 1 & 2
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: